CRESCENT BIOPHARMA, INC. Variable Lease, Cost
CRESCENT BIOPHARMA, INC. (CBIO) reported Variable Lease, Cost of $29.81 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2025-05-14
- CRESCENT BIOPHARMA, INC. variable lease, cost for the quarter ending 2025-03-31 was $29.81K, a 70.15% decline year-over-year.
- CRESCENT BIOPHARMA, INC. variable lease, cost for the quarter ending 2024-12-31 was $138.82K, a 6.34% increase year-over-year.
- CRESCENT BIOPHARMA, INC. variable lease, cost for the quarter ending 2024-09-30 was $138.82K, a 10.77% decline year-over-year.
- CRESCENT BIOPHARMA, INC. variable lease, cost for the quarter ending 2024-06-30 was $138.82K, a 4.36% increase year-over-year.
- CRESCENT BIOPHARMA, INC. variable lease, cost for fiscal 2024 was $516.34K, a 14.29% decline from fiscal 2023.
- CRESCENT BIOPHARMA, INC. variable lease, cost for fiscal 2023 was $602.42K, a 1.63% decline from fiscal 2022.
- CRESCENT BIOPHARMA, INC. variable lease, cost for fiscal 2022 was $612.39K, a 24.76% increase from fiscal 2021.
- CRESCENT BIOPHARMA, INC. variable lease, cost for fiscal 2021 was $490.87K, a 17.36% decline from fiscal 2020.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | $29.81K 10-Q · filed 2025-05-14 | $168.63K derived: sum of 2 quarters · filed 2025-05-14 | $307.45K derived: sum of 3 quarters · filed 2025-05-14 | $446.27K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-12-31 | $138.82K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $277.64K derived: sum of 2 quarters · filed 2025-02-13 | $416.46K derived: sum of 3 quarters · filed 2025-02-13 | $516.34K 10-K · filed 2025-02-13 | |
| 2024-09-30 | $138.82K 10-Q · filed 2024-11-13 | $277.64K derived: sum of 2 quarters · filed 2024-11-13 | $377.52K 10-Q · filed 2024-11-13 | $508.06K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-06-30 | $138.82K 10-Q · filed 2024-08-08 | $238.71K 10-Q · filed 2024-08-08 | $369.24K derived: sum of 3 quarters · filed 2025-05-14 | $524.83K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-03-31 | $99.89K 10-Q · filed 2025-05-14 | $230.42K derived: sum of 2 quarters · filed 2025-05-14 | $386.01K derived: sum of 3 quarters · filed 2025-05-14 | $519.03K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $130.54K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $286.12K derived: sum of 2 quarters · filed 2025-02-13 | $419.14K derived: sum of 3 quarters · filed 2025-02-13 | $602.42K 10-K · filed 2025-02-13 | |
| 2023-09-30 | $155.58K 10-Q · filed 2024-11-13 | $288.61K derived: sum of 2 quarters · filed 2024-11-13 | $471.88K 10-Q · filed 2024-11-13 | $625.63K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $133.02K 10-Q · filed 2024-08-08 | $316.30K 10-Q · filed 2024-08-08 | $470.05K derived: sum of 3 quarters · filed 2024-08-08 | $623.80K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $183.27K 10-Q · filed 2023-05-03 | $337.03K derived: sum of 2 quarters · filed 2024-03-27 | $490.78K derived: sum of 3 quarters · filed 2024-03-27 | $644.53K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-12-31 | $153.75K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $307.51K derived: sum of 2 quarters · filed 2024-03-27 | $461.26K derived: sum of 3 quarters · filed 2024-03-27 | $612.39K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $153.75K 10-Q · filed 2023-11-03 | $307.51K derived: sum of 2 quarters · filed 2023-11-03 | $458.64K 10-Q · filed 2023-11-03 | $605.06K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-06-30 | $153.75K 10-Q · filed 2023-08-02 | $304.88K 10-Q · filed 2023-08-02 | $451.31K derived: sum of 3 quarters · filed 2024-03-27 | $597.73K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-03-31 | $151.13K 10-Q · filed 2023-05-03 | $297.55K derived: sum of 2 quarters · filed 2024-03-27 | $443.97K derived: sum of 3 quarters · filed 2024-03-27 | $495.58K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2021-12-31 | $146.42K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $292.84K derived: sum of 2 quarters · filed 2024-03-27 | $344.45K derived: sum of 3 quarters · filed 2024-03-27 | $490.87K 10-K · filed 2024-03-27 | $490.87M 10-K · filed 2022-03-03 |
| 2021-09-30 | $146.42K 10-Q · filed 2022-11-09 | $198.03K derived: sum of 2 quarters · filed 2022-11-09 | $344.45K 10-Q · filed 2022-11-09 | $488.46K derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-06-30 | $51.61K 10-Q · filed 2022-08-03 | $198.03K 10-Q · filed 2022-08-03 | $342.04K derived: sum of 3 quarters · filed 2023-03-29 | $486.05K derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-03-31 | $146.42K 10-Q · filed 2022-04-28 | $290.43K derived: sum of 2 quarters · filed 2023-03-29 | $434.44K derived: sum of 3 quarters · filed 2023-03-29 | $578.45K derived: sum of 4 quarters · filed 2023-03-29 | |
| 2020-12-31 | $144.01K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $288.02K derived: sum of 2 quarters · filed 2023-03-29 | $432.03K derived: sum of 3 quarters · filed 2023-03-29 | $593.97K 10-K · filed 2023-03-29 | |
| 2020-09-30 | $144.01K 10-Q · filed 2021-11-02 | $288.02K derived: sum of 2 quarters · filed 2021-11-02 | $449.96K 10-Q · filed 2021-11-02 | $465.15M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-06-30 | $144.01K 10-Q · filed 2021-08-05 | $305.95K 10-Q · filed 2021-08-05 | $465.01M derived: sum of 3 quarters · filed 2022-03-03 | $465.16M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-03-31 | $161.95K 10-Q · filed 2021-05-03 | $464.87M derived: sum of 2 quarters · filed 2022-03-03 | $465.01M derived: sum of 3 quarters · filed 2022-03-03 | $465.10M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2019-12-31 | $464.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $464.85M derived: sum of 2 quarters · filed 2022-03-03 | $464.94M derived: sum of 3 quarters · filed 2022-03-03 | $465.03M 10-K · filed 2022-03-03 | $465.03K 10-K · filed 2020-02-28 |
| 2019-09-30 | $148.35K 10-Q · filed 2020-11-06 | $233.08K derived: sum of 2 quarters · filed 2020-11-06 | $324.83K 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $84.72K 10-Q · filed 2020-07-31 | $176.48K 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | $91.76K 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |